Wuxi Apptec (02359) Report Interpretation

Overview

Deutsche Bank reviews Wuxi Apptec’s 1H26 results and maintains a Buy rating. The report sees strong growth, substantial margin improvement, backlog expansion and raised management guidance as support for higher forecasts and a higher DCF-derived target price.

Core views

Wuxi Apptec reported robust 1H26 results. Total revenue reached RMB28,897 million, up 38.9% YoY, while continuing-business revenue rose 48% YoY and represented roughly 55-56% of the initial full-year guidance. Gross profit grew 68.8% YoY to RMB15,382 million. Gross margin improved 9.4 percentage points to 53.2%, which the report attributes to late-stage project progression, capacity ramp-up and better operating efficiency. Lower expense ratios also supported profitability: selling, administrative and R&D expense ratios declined by 0.5, 0.5 and 0.4 percentage points, respectively. Operating margin rose 10.5 percentage points to 44.8%, and adjusted non-IFRS net margin rose 9.7 percentage points to 40.0%. The report highlights WuXi Chemistry as the principal growth driver. Segment revenue increased 53.3% YoY in 1H26, accelerating from 43.7% YoY in 1Q26, while the D&M business grew 72.7% YoY. Management linked this momentum to pipeline progression into later stages, capacity ramp-up and the company’s business model. TIDES revenue increased 44.3% YoY in 1H, with TIDES D&M customers up 39% YoY and molecules up 68% YoY; management expects TIDES to grow about 45% YoY in 2026. WuXi Testing revenue rose 31.5% YoY, including 42.8% YoY growth in drug safety evaluation services, and WuXi Biology grew 11.2% YoY. Management cited improving early-stage-study demand, particularly for new modalities. Earnings visibility is underpinned by backlog growth and raised operating guidance. Continuing-operations backlog grew 25.2% YoY, versus 23.6% YoY in 1Q26; management said growth would have been 30% YoY excluding foreign-exchange effects. Following the first-half performance, management raised its 2026 total-revenue target to RMB58.5-60.5 billion from RMB51.3-53.0 billion. It now expects continuing-business revenue growth of 35-39% YoY, up from 18-22% YoY. The company also lifted 2026 CAPEX guidance to RMB7.5-8.5 billion from RMB6.5-7.5 billion to expand overseas capacity and bring the new Changzhou site forward. Deutsche Bank consequently raises FY26E/FY27E revenue forecasts by 13%/17% and net-profit forecasts by 17%/18%, expecting margin expansion to carry through. Its FY26E revenue forecast rises to RMB59,678 million from RMB52,669 million, with core net profit rising to RMB21,413 million from RMB18,362 million; FY27E revenue rises to RMB72,452 million from RMB61,802 million and core net profit to RMB25,274 million from RMB21,440 million. The report maintains Wuxi Apptec as its top pick in China CRO/CDMO, citing its late-stage and commercial-project position and backlog growth. It notes the shares trade at FY26E/FY27E P/E of 21x/18x, below the five-year historical average despite the broader industry recovery. The target price is raised to HK$207.4 from HK$167.4, entirely due to earnings revisions. Deutsche Bank derives the target from a DCF model using an 8.3% WACC and 2.5% terminal growth rate; the new target implies FY26E/FY27E P/E of 24x/20x. The report reiterates Buy.

Analysis framework

The report first assesses 1H26 revenue, margins and segment performance, then connects backlog growth and management guidance to revised FY26E and FY27E forecasts. It values the company using a DCF framework and cross-checks the implied valuation against forward P/E multiples and the company’s five-year historical average.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  DCF valuation using an 8.3% WACC and 2.5% terminal growth rate

  The report discounts expected future cash flows using its stated cost of capital and terminal-growth assumptions to derive the HK$207.4 target price.

• Valuation methodsP/E and PEG Valuation

  Forward P/E multiple comparison

  The report compares the current FY26E/FY27E P/E of 21x/18x with the five-year historical average and states that the target implies 24x/20x.

• Industry AnalysisVolume-price decomposition

  Segment growth and margin analysis

  The report separates revenue growth by business segment and explains profitability changes through project mix, capacity ramp-up, efficiency and expense ratios.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Wuxi Apptec (02359.HK)

  Primary covered company; the report sees late-stage project progression, capacity ramp-up and backlog growth supporting earnings growth and margins.

  Strengths

  Leading position in late-stage and commercial projects, robust backlog growth, strong WuXi Chemistry momentum and improving margins.

  Comparison

  The report states FY26E/FY27E P/E of 21x/18x is below the company’s five-year historical average despite broader industry recovery.

  Risks

  Geographical tensions, intensifying competition, rising operating costs, drug-price controls and foreign-exchange differences.

Key data

• 1H26 total revenueRMB28,897 millionUp 38.9% YoY; continuing-business revenue rose 48% YoY.
• 1H26 gross margin53.2%Up 9.4 percentage points YoY.
• 1H26 operating margin44.8%Up 10.5 percentage points YoY.
• 1H26 adjusted non-IFRS net margin40.0%Up 9.7 percentage points YoY.
• Continuing-operations backlog growth25.2% YoYManagement said the increase would be 30% YoY excluding foreign-exchange effects.
• 2026 revenue guidanceRMB58.5-60.5 billionRaised from RMB51.3-53.0 billion.
• FY26E/FY27E revenue forecast revision+13% / +17%Driven by strong 1H26 performance and higher management guidance.
• FY26E/FY27E net-profit forecast revision+17% / +18%Supported by expected margin expansion.

Impact & implications

The report considers the combination of late-stage and commercial-project exposure, stronger backlog and raised guidance to improve earnings visibility. It believes higher earnings and margin assumptions justify the increased DCF-based target price while the shares remain below the cited historical forward-P/E average.

Risks

• Geographical tensions may adversely affect the operating environment.
• Market competition could intensify.
• Operating costs could increase.
• Government-initiated drug price-control policy could affect the business.
• Foreign-exchange differences are a risk.

What to watch

• Delivery against the raised 2026 revenue target of RMB58.5-60.5 billion and 35-39% continuing-business growth guidance.
• Whether WuXi Chemistry and TIDES sustain their reported growth momentum.
• Backlog growth, including the effect of foreign exchange.
• Progress in overseas capacity expansion and the accelerated Changzhou site.
• Continuation of margin expansion from project mix, capacity ramp-up and efficiency gains.